These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Bridging of oral anticoagulation with low-molecular-weight heparin: experience in 373 patients with renal insufficiency undergoing invasive procedures. Hammerstingl C; Omran H; Thromb Haemost; 2009 Jun; 101(6):1085-90. PubMed ID: 19492151 [TBL] [Abstract][Full Text] [Related]
3. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment. Kruse MW; Lee JJ Am Heart J; 2004 Oct; 148(4):582-9. PubMed ID: 15459586 [TBL] [Abstract][Full Text] [Related]
4. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Lim W; Dentali F; Eikelboom JW; Crowther MA Ann Intern Med; 2006 May; 144(9):673-84. PubMed ID: 16670137 [TBL] [Abstract][Full Text] [Related]
5. The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial. White HD; Gallo R; Cohen M; Steg PG; Aylward PE; Bode C; Steinhubl S; Montalescot G Am Heart J; 2009 Jan; 157(1):125-31. PubMed ID: 19081408 [TBL] [Abstract][Full Text] [Related]
6. Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Roldán V; Marín F; Fernández H; Manzano-Fernández S; Gallego P; Valdés M; Vicente V; Lip GY Am J Cardiol; 2013 Apr; 111(8):1159-64. PubMed ID: 23337836 [TBL] [Abstract][Full Text] [Related]
7. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Hulot JS; Montalescot G; Lechat P; Collet JP; Ankri A; Urien S Clin Pharmacol Ther; 2005 Jun; 77(6):542-52. PubMed ID: 15961985 [TBL] [Abstract][Full Text] [Related]
8. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure]. Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647 [TBL] [Abstract][Full Text] [Related]
9. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Nutescu EA; Spinler SA; Wittkowsky A; Dager WE Ann Pharmacother; 2009 Jun; 43(6):1064-83. PubMed ID: 19458109 [TBL] [Abstract][Full Text] [Related]
10. Mild to moderate renal impairment is associated with increased left ventricular mass. Greaves K; Chen R; Ge L; Wei M; Tong B; Cai N; Senior R; Hemingway H Int J Cardiol; 2008 Mar; 124(3):384-6. PubMed ID: 17399818 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Spinler SA; Inverso SM; Cohen M; Goodman SG; Stringer KA; Antman EM; Am Heart J; 2003 Jul; 146(1):33-41. PubMed ID: 12851605 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients. Turpie AG; Lensing AW; Fuji T; Boyle DA Blood Coagul Fibrinolysis; 2009 Mar; 20(2):114-21. PubMed ID: 19339838 [TBL] [Abstract][Full Text] [Related]
13. [Perioperative Bridging with Enoxaparin. Results of the Prospective BRAVE Registry with 779 Patients]. Omran H; Hammerstingl C; Paar WD; Med Klin (Munich); 2007 Oct; 102(10):809-15. PubMed ID: 17928964 [TBL] [Abstract][Full Text] [Related]
14. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Fox KA; Piccini JP; Wojdyla D; Becker RC; Halperin JL; Nessel CC; Paolini JF; Hankey GJ; Mahaffey KW; Patel MR; Singer DE; Califf RM Eur Heart J; 2011 Oct; 32(19):2387-94. PubMed ID: 21873708 [TBL] [Abstract][Full Text] [Related]
15. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill? Priglinger U; Delle Karth G; Geppert A; Joukhadar C; Graf S; Berger R; Hülsmann M; Spitzauer S; Pabinger I; Heinz G Crit Care Med; 2003 May; 31(5):1405-9. PubMed ID: 12771610 [TBL] [Abstract][Full Text] [Related]
16. The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial. Fox KA; Antman EM; Montalescot G; Agewall S; SomaRaju B; Verheugt FW; Lopez-Sendon J; Hod H; Murphy SA; Braunwald E J Am Coll Cardiol; 2007 Jun; 49(23):2249-55. PubMed ID: 17560289 [TBL] [Abstract][Full Text] [Related]
17. Administration of enoxaparin by continuous infusion in a naturalistic setting: analysis of renal function and safety. Kane-Gill SL; Feng Y; Bobek MB; Bies RR; Pruchnicki MC; Dasta JF J Clin Pharm Ther; 2005 Jun; 30(3):207-13. PubMed ID: 15896237 [TBL] [Abstract][Full Text] [Related]
18. Individualized dosing of enoxaparin for subjects with renal impairment is superior to conventional dosing at achieving therapeutic concentrations. Barras MA; Duffull SB; Atherton JJ; Green B Ther Drug Monit; 2010 Aug; 32(4):482-8. PubMed ID: 20592650 [TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study. Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794 [TBL] [Abstract][Full Text] [Related]
20. Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation. Feng Y; Green B; Duffull SB; Kane-Gill SL; Bobek MB; Bies RR Br J Clin Pharmacol; 2006 Aug; 62(2):165-76. PubMed ID: 16842391 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]